Myomo to Report Second Quarter 2026 Financial Results on August 5

Key Terms

emg medical

Electromyography (EMG) is a diagnostic test that measures the tiny electrical signals produced by muscles when they contract, using sensors placed on the skin or small needles inserted into the muscle. For investors, EMG results matter when they relate to medical devices, drugs, or therapies because clear improvements or safety signals can indicate clinical benefit and drive regulatory approval, market adoption, and potential revenue—similar to an electrician testing wiring to confirm a building is safe and functional.

orthosis medical

A orthosis is a medical device—such as a brace, splint, shoe insert or support—worn outside the body to support, align, protect or improve the function of a limb or the spine. For investors it signals a part of the healthcare equipment market tied to durable product sales, reimbursement rules, regulatory approvals and ongoing demand from hospitals, clinics and patients; changes in coverage, technology or aging demographics can affect revenue and profit outlooks for companies that make or supply them.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass.--(BUSINESS WIRE)--

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter ended June 30, 2026 on Wednesday, August 5, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions.

Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call can be accessed at https://ir.myomo.com/.

A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at https://ir.myomo.com/. A dial-in replay of the call will be available until August 19, 2026 at 855-669-9658 (U.S. and Canada toll free), or 412-317-0088 (International toll), using access code 1135727.

About Myomo, Inc.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally. For more information, please visit www.myomo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260729211333/en/

Myomo:
ir@myomo.com

Alliance Advisors IR:
Vivian Cervantes
vcervantes@allianceadvisors.com
973-873-7724

Source: Myomo, Inc.